|
Mutation Information
|
Mutation Site
|
M46I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
PR |
|
Relevant Drug
|
bictegravir (BIC);emtricitabine (FTC);tenofovir alafenamide |
|
Country
|
Australia;Europe;North America |
Literature Information
|
PubMed PMID
|
31430369
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2019 |
|
Journal
|
The Journal of antimicrobial chemotherapy |
|
Title
|
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. |
|
Author
|
Andreatta K,Willkom M,Martin R,Chang S,Wei L,Liu H,Liu YP,Graham H,Quirk E,Martin H,White KL |
|
Evidence
|
PI-R substitutions were observed in 10% (55/543), with M46I/L (4.1%, 22/543) and L90M (2.4%, 13/543) most frequently detected.
|
|
|
HIV Mutation Detail Information